Navigation Links
RadMD Reaches 150th Clinical Trial
Date:10/5/2009

DOYLESTOWN, Penn., Oct. 5 /PRNewswire/ -- Completing a major milestone in its three years of operation, RadMD LLC (www.rad-md.net) announced that it has sourced readers for 150 clinical trials.

The most recent trial, conducted by ICON Medical Imaging for a leading pharmaceutical company, was designed to test the efficacy of a new treatment for metastatic kidney cancer. The trial used medical imaging to support the primary analysis of Progression Free Survival based on an independent central radiological review.

"The results of the reads showed that the drug delayed tumor growth by five months, with patients living twice as long without tumor growth as other cancer victims in the study's control arm. Ultimately, this provided the FDA with the information it needed to approve the drug," said Ted Gastineau, president and co-founder, ICON Medical Imaging. "Quality reads are critical and delays cost money and keep drugs from getting to the people who need it most. We are confident that RadMD's blinded readers have the skills and experience necessary to help us support our clients through the drug development process."

RadMD sourced five radiologists with a specialty in oncology within one week of the request and helped with resources and scheduling - allowing completion of the analysis ahead of schedule. Each radiologist received formalized training and extensive testing on a variety of topics related to the use of medical imaging in clinical trials from the company's Blinded Reader and Investigator Training Institute (BRITI)(TM). All CT scans, MRIs and bone scans obtained at baseline during the treatment period and the follow-up period were sent to the independent imaging core lab at ICON Medical Imaging.

Founded by medical imaging experts Kohkan Shamsi, MD, PhD, and Richard Patt, MD, RadMD sources clinical experts and provides consulting services for pharmaceutical, biotech and medical device trials and offers both CME-certified and non-CME courses on medical imaging in clinical trials for both on-site and offsite readers. The company's database of 600 readers come from multiple specialties including radiologists, pathologists, oncologists, cardiologists, medical physicists, medical technologists and others. RadMD has sourced readers for trials in cardiovascular, oncology, neurology, musculoskeletal, endocrinology and sports medicine.

"CRO's and pharmaceutical companies usually manage many concurrent trials and the availability of quality blinded readers saves money, decreases variability and expedites the trial process," said Dr. Shamsi. "By facilitating a key component of the clinical trial process, RadMD helps pharmaceutical, biotech and medical device companies reduce clinical development time, thus getting important anti-cancer and other treatments to the market more quickly."

For more information about RadMD, please visit www.rad-md.net or call 267-247-5544 ext. 500.

About RadMD

RadMD LLC (www.rad-md.net) provides consulting, training, and blinded reader services to the pharmaceutical and biotech industry. Services include defining and developing imaging strategies in clinical development programs, education and training through BRITI (the Blinded Reader & Investigator Training Institute), and the sourcing and management of blinded readers for clinical trials.

BRITI is a trademark of RadMD LLC.

This release, and additional RadMD resources, is available online in the Feintuch Communications media room at www.feintuchcommunications.com.

    Contact:
    Pablo Andreu / Steph Johnson
    Feintuch Communications
    212.808.4903 / 212.808.4904
    pablo@feintuchpr.com / steph@feintuchpr.com

SOURCE RadMD LLC


'/>"/>
SOURCE RadMD LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
3. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
4. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
5. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
6. Genmab Reaches Milestone in Ofatumumab Collaboration
7. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
10. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
11. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... Stock-Callers is currently reviewing the following Medical Appliances ... WMGI ), Varian Medical Systems Inc. (NYSE: VAR ... NuVasive Inc. (NASDAQ: NUVA ). These companies belong ... finish on Thursday, January 12 th , 2017, with the ... health care companies in the S&P 500 were down less ...
(Date:1/13/2017)... , Jan. 13, 2017  Alfalfa, cattle, leafy greens and ... environmental sampling film , which emphasizes the food industry,s shift ... highlights how COPAN,s Swab Rinse Kit ... the surface sampling process in the wake of the new ... COPAN is expanding the U.S. production ...
(Date:1/13/2017)... 13, 2017 On Thursday, January ... Average, and the S&P 500 edged lower at the ... trading session in bearish territories. Taking into consideration yesterday,s ... this morning: Myriad Genetics Inc. (NASDAQ: MYGN ... Research Holdings Inc. (NASDAQ: INCR ), and ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... to provide first-quality education and high-level training standards to an international multidisciplinary group ... eating disorder problems. As a way to further its mission at the grassroots ...
(Date:1/15/2017)... NY (PRWEB) , ... January 15, 2017 , ... In ... accounts in the United States for the asthma & allergy friendly mark. This certification ... to independently test and identify consumer products to be more suitable for the 60+ ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... best physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were ... company managing the award process. Results were announced the magazine’s January 2017 ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to ... magnesium-rich Mediterranean diet may lower the risk of type 2 diabetes, Alzheimer’s, and ... many health and wellness benefits linked to a Mediterranean diet are only some ...
Breaking Medicine News(10 mins):